New depression drug shows promise in early trial

NCT ID NCT06391593

Completed Symptom relief Sponsor: Alto Neuroscience Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called ALTO-203 in 69 adults with moderate major depressive disorder who also had anhedonia (loss of interest or pleasure). Participants received either a low dose, a higher dose, or a placebo, and reported their mood and alertness. The goal was to see if the drug improves mood and is safe over a 28-day period.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANHEDONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anhedonia major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANHEDONIA MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Site 4005

Orlando, Florida, 32801, United States
Site 4007

Clinton, Utah, 84015, United States
Site 4022

Marlton, New Jersey, 08053, United States
Site 4023

Torrance, California, 90504, United States
Site 4031

Atlanta, Georgia, 30030, United States
Site 4033

Bellevue, Washington, 98007, United States
Site 4036

Las Vegas, Nevada, 89121, United States
Site 4040

Austin, Texas, 78737, United States
Site 4054

Pikesville, Maryland, 21208, United States
Site 4058

Tucson, Arizona, 85704, United States
Site 4059

Clermont, Florida, 34711, United States
Site 4072

Houston, Texas, 77081, United States
Site 4075

Westlake, Ohio, 44145, United States
Site 4082

Oceanside, California, 92056, United States
Site 4134

Princeton, New Jersey, 08540, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.